部份中文美沙拉嗪处方资料（仅供参考）
商品名：PENTASA Granules 94%
英文名：Mesalazine
中文名：美沙拉嗪顆粒
生产商：杏林药业
溃疡治疗药：Pentasa(mesalazine)是由Kyorin制药公司开发的高效药。每日-次口服给药，在日本获批用于缓解期溃疡性结肠炎。 
ペンタサ顆粒94％
藥用類別名稱
潰瘍性結腸病治療劑
批准日期：2015年12月
欧文商標名
PENTASA Granules 94%
一般名：メサラジン (Mesalazine) [JAN]
化学名：5-Amino-2-hydroxybenzoic acid
構造式：
分子式：C7H7NO3
分子量：153.14
性状：
本產品為白色、淺灰色或帶紅色白色晶體或結晶性粉末。本產品很難溶于水, 幾乎不溶于乙醇 (99.5)。 本產品熔融成稀鹽酸。
熔點: 270 ~ 275°c(拆卸)
分佈係數: 0.03 (pH3-9, 水-辛醇系統)
藥用藥理學
1. 抑制障礙對動物模型的影響
(1) 潰瘍性結腸炎的相似模型
對美西唑嗪顆粒進行口服, 50在大鼠醋酸誘導模型中, 在100mg/kg時, 在兔分解的卡拉膠誘導模型中觀察到顯著的破壞抑制效果。
(2) 克羅恩病的類似模型
在大鼠tnb誘導模型中, 甲氮唑嗪顆粒50mg/kg口服有明顯的失效抑制作用。
2. 作用機制
觀察體外自由基(dpphl)還原作用、過氧化氫清除作用、次氯酸鹽離子清除作用、脂質過氧化抑制作用(體外、體內)。進一步抑制大鼠中性粒細胞的roy cotriene b4(ltb4)生物合成 (體外)。
從以上, 抹去從炎症細胞釋放的活性氧作為目前的作用的主要機制, 抑制炎症的進展和組織紊亂, 並抑制 ltb4的生物合成, 它認為炎性細胞抑制組織的浸潤。
此外, 作為其他作用機制, 組胺釋放抑制作用從肥大細胞, 生物合成抑制作用血小板啟動劑(paf), 生產抑制效果白細胞介素-1β(il-1β)部分參與了它 (在體外)。
适应症
潰瘍性結腸炎 (嚴重除外), 克羅恩病
用法与用量
潰瘍性結腸炎:
通常情況下, 成人1天1500 毫克作為美西拉嗪口服後口服分為三次, 如有必要, 可以每天服用一次緩解。 此外, 年齡, 它是根據症狀, 每天2天, 250毫克的上限適當調整。
然而, 在活性階段, 如果有必要, 它可以在每天兩次4000 毫克的管理。
通常情況下, 孩子在飯後口服三次, 每天30~60mg/kg 作為甲氮嗪。此外, 年齡, 它是根據症狀, 每天2天, 250毫克的上限適當調整。
克羅恩病:
通常情況下, 成人在飯後口服 1500毫克~3000 毫克, 每天3次。另外, 年齡, 要靠適當的用药症狀。
通常情況下, 孩子在飯後口服三次, 每天 40~60mg/kg 。應該注意的是, 年齡, 根據症狀增加或減少。
包装
顆粒94%
250毫克,含: 0.265克x100膠囊(10粒x10)
500毫克：含:0.53 gx100膠囊 (10粒x10)
1000毫克：含: 1.06 克 x100膠囊 (10粒x10)
2000毫克含: 2.12gx100膠囊(10粒x10)
製造商
杏林药业
注：以上中文不够完整，使用者以原处方资料为准。
完整说明附件：http://www.info.pmda.go.jp/go/pack/2499407G4029_1_06/
Approval received for PENTASA® Granules 94%, atreatment for Ulcerative Colitis and Crohn's Disease
Kyorin Pharmaceutical Co.Ltd.(“Kyorin”)(Head office: Chiyoda-ku,Tokyo, President: Mitsutomo Miyashita), a wholly owned subsidiary of KYORIN Holdings , Inc.announced that Ulcerative Colitis and Crohn's Disease treatment drug of “PENTASA®Granules 94%”(INN: Mesalazine ), received marketing authorization from the Ministry of Health, Labour and Welfare “(MHLW”) on August.
Kyorin  Pharmaceutical has contributed to the treatment of inflammatory bowel diseases (ulcerative colitis and Crohn’s disease) through the launch of  mesalazine formulations such as Pentasa®Tablets (250 mg), Pentasa®Tablets(500mg), Pentasa®Enema(1g), and Pentasa ® Suppositories (1g).
Recently, Kyorin  developed Pentasa®Granules 94% using for the first time its own technology in the country , and has gained approval for this new drug. Pentasa®Granules 94%, which contains  alarge amount of  mesalazine, is a new dosage designed to satisfy therapeutic needs.
Inflammatory bowel diseases are intractable diseases that hinder social interaction, causing frequent diarrhea and melena. The causes have not been identified and there is no radical treatment.
Therefore, the therapeutic goals are suppressing symptoms in the active phase, alleviating the symptoms and keeping the symptoms in a relieved state with the use of mesalazine  drugs like  Pentasa  and steroids.The recently approved drug is a useful granular agent for patients who have difficulty taking pills.
A dose of  Pentasa ® Granules 94%, which contains a large amount of  mesalazine , may be orally given with a single stick (maximum of 2000mg of mesalazine), eliminating the need to take multiple mesalazine  pills when a large amount of mesalazine  is required per dose.
We believe these advantages will help ease the burden of patients taking oral medication and lead to improvements in medication adherence.
Pentasa ® is developed by the Swiss company Ferring, and the tablet form of this drug has been approved in 107 countries for use in treating inflammatory bowel diseases. Granules has been approved in 82 countries worldwide, and is extensively used as the standard treatment for inflammatory bowel diseases.
Kyorin  Pharmaceutical has added  Pentasa®Granules 94% to its existing lineup of dosage forms. Moving forward, it will continue to provide the latest information as it works to support the treatment of patients with inflammatory bowel disease.The timing of the launch and sales projection will be announced at an appropriate time after the NHI price is listed.
1 adherence：While compliance implies that patients follow the instructions of physicians and pharmacists, adherence means that patients should proactively take part in decisions regarding their treatment plans and receive treatment accordingly.